United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

amgen ltd - talimogene laherparepvec - solution for injection - 100mega u/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

amgen ltd - talimogene laherparepvec - solution for injection - 1mega u/1ml

Israel - English - Ministry of Health

amgen europe b.v. - talimogene laherparepvec - solution for injection - talimogene laherparepvec 10^8 pfu / 1 ml - talimogene laherparepvec - imlygic is indicated for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic ( stage iiib, iiic and ivm1a) with no bone, brain, lung or other visceral disease.

Israel - English - Ministry of Health

amgen europe b.v. - talimogene laherparepvec - solution for injection - talimogene laherparepvec 10^6 pfu / 1 ml - talimogene laherparepvec - imlygic is indicated for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic ( stage iiib, iiic and ivm1a) with no bone, brain, lung or other visceral disease.

European Union - English - EMA (European Medicines Agency)

amgen europe b.v. - talimogene laherparepvec - melanoma - antineoplastic agents - imlygic is indicated for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic (stage iiib, iiic and ivm1a) with no bone, brain, lung or other visceral disease.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

amgen ltd - talimogene laherparepvec - solution for injection - 100mega u/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

amgen ltd - talimogene laherparepvec - solution for injection - 1mega u/1ml